Intensity Therapeutics (INTS) Common Equity (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Common Equity came in at $10.0 million in Q1 2026, up 2887.72% YoY from $334000.0 in Q1 2025, and down 15.97% on a QoQ basis from $11.9 million in Q4 2025.
Intensity Therapeutics (INTS) Common Equity (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Common Equity data on file, last reported at $10.0 million in Q1 2026.
- Quarterly Common Equity rose 2887.72% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 2887.72% YoY) and the FY2025 annual result came in at $11.9 million, up 306.99% from the prior year.
- Common Equity slipped to $10.0 million in Q1 2026, from $11.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $15.9 million in Q3 2023 to a low of -$16.0 million in Q1 2023.
- A 5-year average of $2.4 million and a median of $4.1 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity slumped 96.56% — and 2026, when it surged 2887.72%.
- Tracing INTS's Common Equity over 5 years: stood at -$15.1 million in 2022, then soared by 187.18% to $13.2 million in 2023, then slumped by 77.83% to $2.9 million in 2024, then jumped by 306.99% to $11.9 million in 2025, then fell by 15.97% to $10.0 million in 2026.
- The last three Common Equity figures came in at $10.0 million (Q1 2026), $11.9 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 9.79 Bn |
| 10 | Intensity Therapeutics | 12.80 Mn | 12.80 Mn | - | 9.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.21 Mn |
| Mar 31, 2026 | 9.98 Mn |
| Dec 31, 2025 | 11.88 Mn |
| Sep 30, 2025 | 7.22 Mn |
| Jun 30, 2025 | 2.18 Mn |
| Mar 31, 2025 | 334,000.00 |
| Dec 31, 2024 | 2.92 Mn |
| Sep 30, 2024 | 2.78 Mn |
| Jun 30, 2024 | 5.35 Mn |
| Mar 31, 2024 | 9.72 Mn |
| Dec 31, 2023 | 13.16 Mn |
| Sep 30, 2023 | 15.91 Mn |
| Jun 30, 2023 | 15.13 Mn |
| Mar 31, 2023 | -15.96 Mn |
| Dec 31, 2022 | -15.10 Mn |
| Sep 30, 2022 | -14.21 Mn |
| Jun 30, 2022 | -12.48 Mn |